To address the role of different intracellular signals in prolactin (PRL) expression in leukocytes, we have investigated the effects of chlorophenylthio-cAMP (cptcAMP), phorbol myristate acetate (PMA) and ionomycin on the activation of the upstream PRL promoter in several leukemic cell lines. All three stimulators, alone or in synergism with each other, were able to modulate promoter activity, but their actions were cell-type dependent. In freshly isolated peripheral blood mononuclear cells (PBMC), PRL expression could only be stimulated by cptcAMP. The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E 2 and the h 2 -adrenergic agonist terbutaline, which both signal through cAMP. D
Introduction
PRL is a 23-kDa polypeptide hormone that is produced mainly by the anterior lobe of the pituitary. The best known function of pituitary-derived PRL is the initiation and maintenance of lactation. However, PRL is a pleiotropic and versatile hormone that also plays a role in reproduction, angiogenesis and modulation of immune responses. Indeed, PRL receptors are widely distributed in a variety of tissues. Furthermore, several extrapituitary sources of PRL have been described and it is now well established that prolactin is expressed in the decidua, the brain, the mammary gland and in cells of the immune system (Ben Jonathan et al., 1996; Kooijman et al., 2000a) . The fact that PRL subserves many different functions can, in part, be explained by tissuespecific regulation of PRL expression. Regulation of PRL expression in the pituitary has been extensively studied, but the regulation of ectopic PRL expression has remained relatively unexplored. The classical modulators of pituitary PRL expression [i.e. dopamine, thyrotropin releasing hormone (TRH) and estrogen] are unable to regulate extrapituitary PRL expression (Gellersen et al., 1989; Handwerger et al., 1991; Bonhoff and Gellersen, 1994) . This can be explained by the finding that in humans transcription in extrapituitary tissues is directed by an alternative promoter located 5.8 kb upstream of the pituitary-specific start site (Berwaer et al., 1994; Gellersen et al., 1994) . Due to the presence of a 5Vnon-coding exon (exon 1a), the extrapituitary transcript of the PRL gene is 150 nucleotides longer than its pituitary counterpart. The PRL peptide produced by decidua and lymphocytes is, however, indistinguishable from that of pituitary origin.
In the immune system, the PRL receptor, which belongs to the cytokine-receptor superfamily, is expressed on T-cells, B-cells, monocytes, and NK-cells (Pellegrini et al., 1992; Matera, 1996) . Although PRL does not seem to be required for immune responses under normal circumstances in mice (Horseman et al., 1997) , there is nevertheless compelling evidence for modulatory actions of PRL on both humoraland cell-mediated immune responses. For instance, PRL enhances the expression of inducible nitric oxide synthetase, immunoglobulins, and cytokines in human leukocytes (Dogusan et al., 2000; Jacobi et al., 2001; Lahat et al., 1993; Matera et al., 1999; Cesario et al., 1994) . The immunomodulatory effects of PRL suggest that it plays a role in the communication between the neuroendocrine system and the immune system. Indeed, pituitary PRL secretion is regulated
